Author

Brandon C. Clavette

Observed name: Brandon Clavette

Institution: Zymeworks (Canada)

Observed institution: Zymeworks (Canada)

ORCID: 0000-0003-0340-4396

Observed ORCID: 0000-0003-0340-4396

OpenAlex ID: A5082830770

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

2018 · Elizabeth A. Killion, Jinghong Wang, et al. · Science Translational Medicine · 244

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

2012 · David W. Jenkins, Sarah Ross, et al. · Molecular Cancer Therapeutics · 52

Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2

2023 · Meghan M. Verstraete, Florian Heinkel, et al. · mAbs · 12

Abstract 2926: PROTECTTM, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action

2023 · Anna von Rossum, Genevieve Desjardins, et al. · Cancer Research · 2

Supplementary Figure 1 from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

2023 · David W. Jenkins, Sarah Ross, et al.

Supplementary Methods, Figure Legend from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

2023 · David W. Jenkins, Sarah Ross, et al.

Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

2023 · David W. Jenkins, Sarah Ross, et al.

Data from MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

2023 · David W. Jenkins, Sarah Ross, et al.

Abstract 1737: Understanding the geometry and valency of bispecific antibodies in the optimization of tumor-dependent activation of 4-1BB

2021 · Anna von Rossum, Harsh Pratap, et al. · Cancer Research

Works count: 9

Citation count: 310

H-index: 3

I10-index: 3